These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 6231806)

  • 1. Zimeldine treatment of obsessive-compulsive disorder. Biological and neuropsychological aspects.
    Kahn RS; Westenberg HG; Jolles J
    Acta Psychiatr Scand; 1984 Mar; 69(3):259-61. PubMed ID: 6231806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double blind study of imipramine versus zimelidine in treatment of obsessive compulsive neurosis.
    Prasad A
    Pharmacopsychiatry; 1984 Mar; 17(2):61-2. PubMed ID: 6233622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obsessive-compulsive disorder and serotonin: is there a connection?
    Insel TR; Mueller EA; Alterman I; Linnoila M; Murphy DL
    Biol Psychiatry; 1985 Nov; 20(11):1174-88. PubMed ID: 2413912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine treatment of obsessive-compulsive disorder.
    Perse TL; Greist JH; Jefferson JW; Rosenfeld R; Dar R
    Am J Psychiatry; 1987 Dec; 144(12):1543-8. PubMed ID: 3120604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological and neuropsychological studies of patients with obsessive-compulsive disorder.
    Insel TR; Donnelly EF; Lalakea ML; Alterman IS; Murphy DL
    Biol Psychiatry; 1983 Jul; 18(7):741-51. PubMed ID: 6615935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial.
    Vallejo J; Olivares J; Marcos T; Bulbena A; Menchón JM
    Br J Psychiatry; 1992 Nov; 161():665-70. PubMed ID: 1422616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug treatment of obsessive-compulsive disorder: a review of findings in the light of diagnostic and metric limitations.
    Towbin KE; Leckman JF; Cohen DJ
    Psychiatr Dev; 1987; 5(1):25-50. PubMed ID: 2885832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
    Eriksson T
    Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alprazolam in the treatment of obsessive symptoms.
    Tollefson G
    J Clin Psychopharmacol; 1985 Feb; 5(1):39-42. PubMed ID: 3973070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nicotine treatment of obsessive-compulsive disorder.
    Lundberg S; Carlsson A; Norfeldt P; Carlsson ML
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Nov; 28(7):1195-9. PubMed ID: 15610934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder.
    Dougherty DD; Corse AK; Chou T; Duffy A; Arulpragasam AR; Deckersbach T; Jenike MA; Keuthen NJ
    Int J Neuropsychopharmacol; 2015; 18(2):. PubMed ID: 25637377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open trial of fluoxetine in obsessive-compulsive disorder.
    Jenike MA; Buttolph L; Baer L; Ricciardi J; Holland A
    Am J Psychiatry; 1989 Jul; 146(7):909-11. PubMed ID: 2787123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
    Liebowitz MR; Hollander E; Schneier F; Campeas R; Hatterer J; Papp L; Fairbanks J; Sandberg D; Davies S; Stein M
    J Clin Psychopharmacol; 1989 Dec; 9(6):423-7. PubMed ID: 2687337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder.
    Fontaine R; Chouinard G
    J Clin Psychopharmacol; 1986 Apr; 6(2):98-101. PubMed ID: 3517083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Obsessive-compulsive symptoms associated with panic disorder. Predictive factor of a good therapeutic response to fluvoxamine].
    Servant D; Bailly D; Le Seac'h H; Parquet PJ
    Encephale; 1990; 16 Spec No():359-62. PubMed ID: 2120029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder.
    McDougle CJ; Barr LC; Goodman WK; Pelton GH; Aronson SC; Anand A; Price LH
    Am J Psychiatry; 1995 Dec; 152(12):1812-4. PubMed ID: 8526253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychological profile of schizophrenia with and without obsessive compulsive disorder.
    Kazhungil F; Kumar KJ; Viswanath B; Shankar RG; Kandavel T; Math SB; Venkatasubramanian G; Reddy YCJ
    Asian J Psychiatr; 2017 Oct; 29():30-34. PubMed ID: 29061423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A; Rosenthal J; Nezu A; Winston A
    Mt Sinai J Med; 1990 Nov; 57(6):348-52. PubMed ID: 2079952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obsessive-compulsive disorder.
    Insel TR
    Psychiatr Clin North Am; 1985 Mar; 8(1):105-17. PubMed ID: 3887336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuropsychological performance in children and adolescents with obsessive-compulsive disorder and influence of clinical variables.
    Andrés S; Boget T; Lázaro L; Penadés R; Morer A; Salamero M; Castro-Fornieles J
    Biol Psychiatry; 2007 Apr; 61(8):946-51. PubMed ID: 17157271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.